/stocks — the workspaceLOADING
All SOPH SEC filings, by type → · Earnings date & implied move · Search inside filings
SOPHiA GENETICS SA (SOPH) is a services-computer processing & data preparation company. 33 insider Form 4 filings in the last 90 days. Fundamentals from SEC filings; prices are end-of-day.
What’s behind SOPH’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
No recent 10-K / 10-Q / 8-K filings found.
Has SOPH been issuing shares? Offering history →
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
Not reported in XBRL for this filer.
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as SOPH tagged it, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
A plain-English read on SOPH plus an auto-SWOT — built from SOPH's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate SOPH using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
Projected from SOPH's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentSOPH files or announces.
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
Volume against its own history: 77% of its last 252 sessions were lighter than the last one. Volume detail
Closes only, split-adjusted. An average needs that many sessions on file to print. These are measurements, not support, resistance or targets. Chart with studies
No fair value band on this page build. No annual filing figures reached the estimators, either because the SEC read did not finish or because SOPH has not filed annual figures yet. That is a statement about the read, not about SOPH’s value. The page rebuilds daily.
Every refusal recorded for SOPH → · How often we decline, and why →
Total return including reinvested dividends, from SOPH’s adjusted closing prices. Past return is not a forecast and not investment advice.
No lawmaker has disclosed a trade in SOPH under the STOCK Act.
| Generation Investment Management (Al Gore) | $39.2M | 0.4% of portfolio |
| Akre Capital Management (Chuck Akre) | $21.5M | 0.4% of portfolio |
2 of the 64 tracked funds hold SOPH among their 25 largest positions. A co-holding count needs at least 3 holding funds, because fewer is one or two portfolios read aloud, so no list is shown.
Head office: Rolle, Switzerland
Source: the cover page of SOPHiA GENETICS SA’s 20-F filed 2026-03-03, on EDGAR. Filings checked 2026-11-02. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Of 24 sales in the last ~6 months, 22 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 2 were filed without it.
| Menu PhilippeChief Medical Officer | SELLplan | $36K | view → |
| Xu ZhenyuChief Scientific Officer | SELLplan | $29K | view → |
| Camblong JurgiExecutive Chairman | SELLplan | $62K | view → |
| Van Well DaanChief Legal Officer | SELLplan | $50K | view → |
| Valente ManuelaChief People Officer | SELLplan | $34K | view → |
| Verma AbhimanyuChief Technology Officer | SELLplan | $43K | view → |
| Puylaert KevinChief Sales Officer | SELL | $2K | view → |
| CARDOZA GEORGEChief Financial Officer | SELLplan | $13K | view → |
2 of the 2 checks that ran found nothing new for SOPH. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.